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Figure 3A. Overall mortality in HSCT recipients. 3B. Mortailty among patients with TMA
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tem (PHIS), an electronic database of children’s hospitals
in the US. Patients under the age of 21 who underwent
HSCT at one of the 42 PHIS hospitals from 2000-2012 were
analyzed. We abstracted data on demographics, hospital-
izations, TMA and other HSCT related complications.
Results: From 2000 to 2012, a total of 12369 unique pedi-
atric patients who received HSCT were identiﬁed. Among
these 93 (0.8%) children were identiﬁed to have the diag-
nosis of TMA. Overall, there was an increasing trend of TMA
diagnosis seen in our cohort (Figure 1). The demographic
characteristics, risk factors and outcome of these children
with and without TMA are shown in Figure 2. TMA was
signiﬁcantly associated with allogeneic HSCT (p¼<0.001),
PBSCT (p¼0.045), CMV (p¼<0.001), HHV6 (p¼<0.001),
fungal infection (p¼<0.001), GVHD (p¼<0.001) and VOD
(p¼0.01). The mortality was signiﬁcantly higher in patients
with TMA compared to those without (30.1% vs. 12.2%,
p¼<0.001, Figure 3A). Also, median time (days) to mor-
tality following HSCT was shorter in patients with TMA
than those without (754 [365, 1614] vs. 1439 [552, 2847],
p¼<0.0001). Multivariate logistic regression analysis of
mortality using age, gender, HSCT type, CMV, HHV6, fungal
infection and plasmapheresis showed only HHV6 was an
independent risk factor associated with increased mortal-
ity in patients with TMA (Hazard Ratio: 2.86 [1.01, 8.39],
p¼0.05) (Figure 3B).
Conclusions: Ours is the largest cohort of TMA following
HSCT in children. The prevalence of TMA in our study is
0.8% with an increasing trend in recent years. The mortality
in our pediatric TMA cohort is 30% which is in contrast to
the higher mortality reported in previously published
small case series. HHV6 emerged as not only a risk factor
for TMA but also associated with increased mortality in
these patients. Plasmapheresis was not associated with
improved survival in our study. Studies exploring the
pathophysiology of TMA and its relationship to other
complications of HSCT are needed to optimize the out-
come.86
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Allogenic stem cell transplantation is the only curative op-
tion for patients with inherited bone marrow failure syn-
drome such as congenital amegakaryocytic thrombopenia
disease (CAMT). This multicenter retrospective study is
based on data reported to the EBMT registry on patients with
CAMT who underwent allogeneic hematopoietic stem cell
transplantation from 1987 to 2013. Sixty three patients with
CAMT were transplanted with identical sibling donor
(n¼25), matched unrelated donor (n¼25), matched other
relative (n¼5) and mismatched donor (n¼8). Stem cell
source were bone marrow (n¼31) or peripherical blood
(n¼21) or cord blood (n¼11). Age at HSCT varied from 6
months to seventeen years. Conditioning regimen was
available for 50 patients : 41 (82%) patients received mye-
loablative conditioning regimen and 9 (18%) patients
reduced intensity one. The median time for neutrophil re-
covery was nineteen days. Cumulative incidence of grade II-
IV aGvHD was 13%. Cumulative incidence of chronic exten-
sive GvHD was 6.3%. 5 year-overall survival was 76.6%+/-7
and TRM is 12.6%+/-4 with no difference by age, gender, year
of transplant, HLA compatibility and stem cell source. 53
(84%) patients were alive at last follow up. Nine patients
(14.3%) died, seven from HSCT, one from disease and two
from other causes. Eleven patients underwent second HSCT
and six patients third HSCT. From them, four patients died
and seven were alive, six were free of disease and one still
with CAMT. This study is the wider reported so far and
conﬁrms that CAMT in children can successfully be treated
by allogenic stem cell transplantation. Patients who lack a
Abstracts / Biol Blood Marrow Transplant 20 (2014) S72eS90S82suitable related match have to be considered for alternative
HSCT.87
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Introduction: Since 1991, three sequential prospective
multi-national clinical trials (including 39 participating in-
stitutions) have been conducted by the “Head Start” Con-
sortium for young children newly-diagnosed with malignant
brain tumors, designed to improve both the cure rate and
quality of survival of such children through replace-
ment (<6yo) or reduction in dosage of brain irradiation (6-
10yo) by a single cycle of marrow-ablative chemotherapy
with autologous hematopoieic cell rescue as consolidation
following initial induction chemotherapy. We present data
documenting progressively decreasing morbidity and mor-
tality of the marrow-ablative consolidation phase of treat-
ment as well as the improvement in disease-speciﬁc survival.
Methods: Overall treatment design has remained un-
changed throughout the 3 prospective trials; 5 cycles of in-
duction chemotherapy (vincristine, cisplatin, etoposide,
cyclophosphamide with/without high-dose methotrexate
(HD-MTX) over 4 days each 21-28 days cycle (HSI-II) or 3
cycles of the prior regimen + HD-MTX alternating with 2
cycles of vincristine, oral etoposide, temozolomide and
cyclophosphamide) were followed efor patients with mini-
mal residual, non-progressive tumor - by a single marrow-
ablative cycle consisting of thiotepa (300mg/M2/day x 3
days), etoposide (250mg/M2/day x 3 days) on days -5 to -3,
preceded by carboplatin (500mg/M2/day or AUC of 6/day by
Calvert formula, whichever was the lower of the methods of
dosing) on days -8 to -6. Bone Marrow (HSI) or leukapher-
esed peripheral blood hematopoietic cells under Neupogen
stimulation (HSII-III) were obtained following recovery
from the ﬁrst and/or second induction cycles. Radiotherapy
was reserved for patients with residual tumor following
completion of induction or >6yo.
Results: A total of 216 children were enrolled on 3 consec-
utive HS trials with medulloblastoma, other primitive neuro-
ectodermal tumors, ependymoma, atypical teratoid/rhab-
doid tumors, malignant glial tumors and other malignant
CNS tumors and underwent marrow-ablative chemotherapy,
the 100 day toxic mortality for whom steadily declined from
HSI (3/37¼8.1%; 1 day +4 hepato-renal failure; 1 day +26 viral
pneumonitis post-multi-organ system failure; 1 day +21
post-respiratory arrest due to oropharyngeal mucositis)
through HSII (1/46¼2.2%; pseudomonas aerugenosa sepsis)
to HSIII (1/131 ¼ 0.8%; VOD day +21). Data on time to
engraftment, transplant-related morbidities and long-term
disease-speciﬁc survival will also be presented.
Conclusions: Increasing experience with the marrow-abla-
tive chemotherapy regimen, combined with improved leu-
kapheresis and post-reinfusion supportive care techniques,
have likely contributed to the steady decline in transplant-
related mortality in this patient population and contributed
towards improved overall survival.88
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Background: TBI-based preparative regimen has been
widely recommended for pediatric ALL. These assumptions
are based on older registry studies. Because of the signiﬁ-
cantly high rates of serious late effect using TBI in pediatric
patients it is of utmost importance to ﬁnd alternative regi-
mens. Chemotherapy regimens are developed to minimize
the toxicities of irradiation-based regimens.
Methods: Since the year 1994, 111 pediatric patients (78
male &33 female: 72 in CR and 39 not in CR) with ALL un-
derwent HSCT in our center using a TBI-free conditioning.
Here, we describe the outcomes of HSCT of the 72 patients in
CR: 30 patients were in ﬁrst CR, 28 second CR, and 14 third
CR. Only very high-risk patients underwent HSCT in the ﬁrst
CR. Patients were treated and classiﬁed according to BFM
protocols. The conditioning regimen was included of
Busulfan (IV or Oral) and Cyclophosphamide with or without
ATG. For GVHD prophylaxis, patients received cyclosporine
with or without methotrexate.
Outcomes: Patients underwent transplantation from sib-
ling donors (n¼58), other related donors (n¼10), unre-
lated donor (n¼4). Source of grafts were peripheral blood
(n¼60), bone marrow (n¼7) and cord blood (n¼5). The
probability of neutrophil engraftment (at day60) was 94+-
3% (med.time to of 14days) and of platelets-engraftment
was 90+-10% (med.time 22days). The estimated 5-year
leukemic free survival (LFS) was 73%+-6% (82+-7% in CR1,
71+-10% in CR2 and 38+-25% in CR>¼2). Relapse rates
were 8+-5% in CR1, 22+-9% in CR2 and 20+-17% in CR>¼2.
Acute GvHD grade 2-4 occurred in 49+-5% patients and
15+-5% patients have experienced chronic extended
GvHD.
Conclusion: A TBI-free (Bu/Cy) preparative regimens can be
used in pediatric ALL with encouraging LFS rates, similar to
what is reported in literature using TBI. Well-designed ran-
domized trials are needed to better clarify the difference
between radiation and TBI-free conditioning regimens in
pediatric ALL, including late effects.
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In 2009, we initiated a prospective study of chimerism-
based preemptive IT consisting of fast withdrawal of
